You are using a browser that is either out of date or not supported.
HIBM.ORG is best viewed using Firefox, Safari, Opera, or IE 6+.
Thank you for your attention.

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
about_arm:marlene_haffner [2011/05/11 04:14] – external edit 127.0.0.1about_arm:marlene_haffner [2014/05/04 17:38] (current) – external edit 127.0.0.1
Line 2: Line 2:
  
 {{  about_arm:marlene_haffner.jpg?200| Dr. Marlene Haffner}} {{  about_arm:marlene_haffner.jpg?200| Dr. Marlene Haffner}}
-Dr. Marlene E. Haffner has been involved with rare diseases for her entire medical and public health career.  For 20 years she directed the Office of Orphan Products Development in the FDA.  While in that position she was introduced to ARM and immediately became excited about their work and their energy.  Marlene is a graduate of the George Washington University School of Medicine and the Johns Hopkins University Bloomberg School of Public Health.  Her passion is making a difference in the lives of people so that their lives can be healthier and more productive.  During her time with the Office of Orphan Products she oversaw the FDA approval of more than 300 products to treat rare diseases and more than 1000 in some stage of development toward FDA approval.  Since 2007 she has been Executive DirectorRegulatory Affairs at AmgenInc.+Dr. Marlene E. Haffner has been involved with rare diseases for her entire medical and public health career.  For 20 years she directed the Office of Orphan Products Development in the FDA.  While in that position she was introduced to ARM and immediately became excited about their work and their energy.  Marlene is a graduate of the George Washington University School of Medicine and the Johns Hopkins University Bloomberg School of Public Health.  Her passion is making a difference in the lives of people so that their lives can be healthier and more productive.  During her time with the Office of Orphan Products she oversaw the FDA approval of more than 300 products to treat rare diseases and more than 1000 in some stage of development toward FDA approval.   
 + 
 +CurrentlyDr. Haffner is the president and CEO of [[http://mhaffner.com/ | Haffner AssociatesLLC]].